Chemours (NYSE: CC) director Erin Kane granted 7,182 stock units

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Chemours Co director Erin N. Kane received a grant of 7,182 Chemours common stock units as board compensation. The award was recorded at a price of $0.00 per unit and increases Kane’s directly held stock units to 74,062.9086.

The footnotes explain these are stock units that will convert one-for-one into Chemours common shares when Kane separates from service on the Board, and that the total includes both deferred stock units and related dividend equivalent units. This is a non-cash, routine equity award rather than an open-market purchase.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Kane Erin N

Role null

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	7,182	$0.00	--

Holdings After Transaction: Common Stock — 74,062.909 shares (Direct, null)

Footnotes (1)

Represents stock units that will convert one-for-one to Chemours common stock upon separation from service on the Board. Includes deferred stock units and dividend equivalent units.

Key Figures

Stock units granted: 7,182 units Grant price: $0.00 per unit Total units after grant: 74,062.9086 units

3 metrics

Stock units granted 7,182 units Director stock award on May 6, 2026

Grant price $0.00 per unit Compensation grant, non-cash transaction

Total units after grant 74,062.9086 units Direct holdings following the reported transaction

Key Terms

stock units, deferred stock units, dividend equivalent units

3 terms

stock units financial

"Represents stock units that will convert one-for-one to Chemours common stock"

Stock units are individual pieces of ownership in a company, like slices of a pie that together make up the whole business. They matter to investors because each unit represents a claim on the company’s assets, profits and sometimes voting power, and changes in the number or value of these units affect ownership percentages, potential dividends and share dilution — all of which influence an investment’s worth.

deferred stock units financial

"Includes deferred stock units and dividend equivalent units."

Deferred stock units are promises from a company to give an employee shares of stock at a future date, often after certain conditions are met or after leaving the company. They function like a form of delayed compensation, allowing employees to earn shares over time. For investors, they represent potential future ownership in the company, but do not provide immediate voting rights or dividends until the shares are actually received.

dividend equivalent units financial

"Includes deferred stock units and dividend equivalent units."

Dividend equivalent units are bookkeeping credits that mirror cash dividends paid on actual shares, granted to holders of stock-based awards such as restricted stock units or deferred compensation. They matter to investors because they increase a company’s reported employee compensation cost and can lead to issuance of more shares or cash payouts over time, similar to extra pay linked to ownership that affects shareholder dilution and corporate cash flow.

Form 4 Insider Transactions: What Each Field Means →

05/08/2026 - 04:15 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kane Erin N

(Last)

(First)

(Middle)

C/O THE CHEMOURS COMPANY

1007 MARKET STREET

(Street)

WILMINGTON

DELAWARE

19801

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Chemours Co [ CC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/06/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	05/06/2026		A		7,182⁽¹⁾	A	$0	74,062.9086⁽²⁾	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Represents stock units that will convert one-for-one to Chemours common stock upon separation from service on the Board.

2. Includes deferred stock units and dividend equivalent units.

	/s/ Eric Stein, Attorney-in-Fact	05/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Chemours (CC) director Erin N. Kane report?

Chemours director Erin N. Kane reported receiving 7,182 stock units as a board compensation award. These units are granted at no cash cost and increase her directly held stock-based position to 74,062.9086 units tied to Chemours common stock.

Are Erin N. Kane’s new Chemours (CC) shares a purchase or a grant?

The filing shows a grant, not a market purchase. Transaction code A indicates a grant, award, or other acquisition, with 7,182 stock units issued at a stated price of $0.00 per unit as part of director compensation.

When do Erin N. Kane’s Chemours (CC) stock units convert into common shares?

The footnotes state the stock units will convert one-for-one into Chemours common stock when Erin N. Kane separates from service on the Board. Until that time, the position is held as stock units rather than currently issued common shares.

What is included in the 74,062.9086 Chemours (CC) units held by Erin N. Kane?

The total 74,062.9086 units following the transaction includes deferred stock units and associated dividend equivalent units. These units track Chemours common stock on a one-for-one basis and are designed to convert into shares at board service separation.

Did Chemours (CC) director Erin N. Kane sell any shares in this Form 4 filing?

No sales are reported in this Form 4. The transaction summary shows one acquisition transaction and zero dispositions, with 7,182 stock units granted and no open-market sales or other share disposals disclosed in the data provided.